Phospho-TMEM173/STING (Ser366) Antibody - #AF7416

Fig. 5. CPC inhibits cGAS-STING pathway activation. (A) Mechanism of CPC inhibiting the activation of cGAS-STING signaling pathway. (B) Immunofluorescence staining and colocalization quantification of DAPI/TOM20/dsDNA in H9C2 cells from different treatment groups. Cytoplasmic dsDNA is indicated by yellow arrow, scale bar: 20 μm. (C) Quantitative real-time PCR analysis of mtDNA: mtDNA content was normalized to nuclear DNA. (D) Determination of the level of cGAMP in H9C2 cells. (E–I) WB of cGAS-STING pathway-related proteins in H9C2 cells, including representative images and quantitative analysis of cGAS, P-STING/STING, P-NF-κB/NF-κB and P-IRF3/IRF3. (J) Determination of the level of IL-1β in H9C2 cells. (K) Determination of the level of IL-6 in H9C2 cells. (L) Immunofluorescence staining of DAPI/TOM20/dsDNA in heart tissue from different treatment groups, the cytoplasmic dsDNA is indicated by yellow arrow, scale bar: 20 μm and 10 μm. (M) The colocalization analysis of DAPI/TOM20/dsDNA in heart tissues: the intensity profiles of the fluorescence signals. (N) Representative images of cGAS and P-STING immunohistochemical staining in heart tissues of different treatment groups, scale bar: 50 μm. Data were expressed as mean ± SE. Statistical significance was performed by one-way ANOVA with Tukey post hoc test. (n = 3, ns: P > 0.05, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).